Plain Facts compilation, we present to you data-based insights, with easy-to-read charts, to help you delve deeper into the ...

This summary covers recent developments in health from the death tied to a cyberattack on Synnovis services in the UK, the Eli Lilly and Novo Nordisk rivalry in the weight-loss drug market in India, ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...

A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may ...